ELEGEN

Our #EmployeeSpotlight is on David Dodd, Director of Chemistry! David carries responsibilities critical to #TeamElegen’s success, driving increasingly efficient #genesynthesis using novel chemistries.🧬We’re #LuckytoHaveYou—thanks for all you do! 🎉 Read more about David: https://hubs.ly/Q0301dnk0 #EmployeeAppreciation #BayAreaJobs #SanFrancisco

Huge congrats to Genentech for their publication “Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses” in Analytical Chemistry (American Chemical Society). Their team examined abortive transcripts, poly(A) tail length, and dsRNA byproducts to determine structure–function relationships that may affect safety or limit efficacy of cellular responses. Great step forward for mRNA therapeutics! https://hubs.ly/Q02_Wnvn0 #AnalyticalChemistry #polyA #mRNAvaccines #GeneticMedicines #IVTreadyDNA #mRNAtherapeutics #CellFreeCloning 

ELEGEN founder and CEO Matthew Hill will be attending the 2025 J.P. Morgan Healthcare Conference Jan 13-16, along with CBO @Dan La Caze. Schedule a time to connect and hear how biopharma are incorporating ENFINIA DNA, manufactured cell free, full length, and NGS verified, to fast-track mRNA vaccine and genetic medicine workflows. Email [email protected]! #cellfreecloning #EnfiniaDNA #genesynthesis #mRNAVaccine #JPMorgan

We’ve moved! 🎉It’s been a great year of growth for ELEGEN—both #hiring and product adoption. We’re now in a new location that enables us to occupy the entire building, allowing even greater expansion to keep up with the demand for cell-free production of full-length, NGS-verified #EnfiniaDNA in 2025! #cellfreecloning #genesynthesis #DNAinnovation

As we continue to recap highlights of 2024, our Series B fundraising round at $35 million is high on the list! Thx to our investors for believing in our mission to accelerate upstream & downstream mRNA vaccine and genetic medicine workflows with cell-free, NGS-verified, full-length ENFINIA DNA delivered as fast as 6 days!  🎉🙌Shoutout to Triatomic Capital, GSK, @John Ballentyne, #AndreessenHorowitz ( a16z Bio + Health), KdT Ventures, 8VC, Digitalis Ventures, ACVC Partners, Alix Ventures, AME Cloud Ventures and Agilent Technologies!  Read more: https://bit.ly/4guiOBY #SeriesB #mRNAvaccines #GeneticMedicines #cellfreecloning #DNAinnovation #syntheticDNA #genesynthesis

Do you know any #TechTalent looking for work? ELEGEN is #hiring! Our Operations and R&D departments are looking to build out their teams. Check out these openings and more:  https://bit.ly/3OPMLRp #biotech #SanFrancisco #BayAreaJobs #GeneSynthesis

“Synthetic DNA as an Alternative to Plasmids” in the latest issue of BioPharm International discusses advanced cell-free technologies with higher-throughput, smaller footprints, and more repeatable in vitro approaches to replace fickle cells. Specific advantages include high yields, simpler purification, no concern about bacterial or antibiotic resistance genes, reduced risk of residual host-DNA and endotoxin impurities, and a smaller footprint allowing scale flexibility with efficiency and speed. Read more: https://bit.ly/4ik79aK #syntheticDNA #genesynthesis #cellfreecloning Cynthia Challener

It’s fun to look back at this time of year to take stock of accomplishments – and we started 2024 with a 🎉, announcing our multi-year collaboration with GSK! It’s been an exciting year of partnering to provide a fast, turnkey supply of long, high accuracy, complex ENFINIA DNA🧬 to accelerate their dev and clinical production of mRNA vaccine and genetic medicine pipelines. Check out Genetic Engineering & Biotechnology News’ coverage: https://bit.ly/41k0BCR #EnfiniaDNA #mRNAvaccines #GeneticMedicines #syntheticDNA #genesynthesis

Help us #WelcomeOnboard Tiffany Cheung as Project Manager, Lab Automation! Tiffany joins #TeamElegen with expertise in high-throughput, robust, walkaway lab robotics and automation. We can’t wait to see the efficiencies she brings to our next-gen cell-free gene synthesis! #hiring #bayareajobs #SanFrancisco #biotech #genesynthesis

Discover how next-generation cell-free gene synthesis technology is helping to advance areas such as TCR engineering, CAR-T therapies, gene editing, and mRNA vaccines! Watch the recent Cell & Gene Therapy Showcase webinar on demand, hosted by Drug Discovery World: https://bit.ly/41m4dnQ #CARTtherapy #TCRtherapy #genesynthesis #mRNAvaccines #CGT Galit Meshulam-Simon Jacqueline Barry Victor Dillard Lara Campana Neal Flomenberg Hinnah Campwala Tim L. Haley Merritt, PhD